Mouse CXCL10/IP-10/CRG-2 Quantikine ELISA Kit
| Name | Mouse CXCL10/IP-10/CRG-2 Quantikine ELISA Kit |
|---|---|
| Supplier | R&D Systems |
| Catalog | MCX100 |
| Category | ELISA Kit |
| Prices | $479.00, $2,299.00 |
| Sizes | 1 kit, 1 pack (6 Plates) |
| Assay Type | Solid Phase Sandwich ELISA |
| Sensitivity | 4.2 pg/mL |
| Range | 31.20 - 2,000 pg/mL (Cell Culture Supernates, Serum, Heparin Plasma,) |
| Format | 96-well strip plate |
| Applications | ELISA |
| Species Reactivities | Mouse |
| Description | The Quantikine Mouse IP-10 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure mouse IP-10 in cell culture supernates, serum, and plasma |
| Gene | CXCL10 |
| Supplier Page | Shop |
Product images
Product References
Deregulation of type I IFN-dependent genes correlates with increased - Deregulation of type I IFN-dependent genes correlates with increased
Ostermann E, Tuddenham L, Macquin C, Alsaleh G, Schreiber-Becker J, Tanguy M, Bahram S, Pfeffer S, Georgel P. PLoS One. 2012;7(8):e43744.
Chemokine receptor CXCR3 promotes growth of glioma. - Chemokine receptor CXCR3 promotes growth of glioma.
Liu C, Luo D, Reynolds BA, Meher G, Katritzky AR, Lu B, Gerard CJ, Bhadha CP, Harrison JK. Carcinogenesis. 2011 Feb;32(2):129-37.
Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the - Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the
Campanella GS, Tager AM, El Khoury JK, Thomas SY, Abrazinski TA, Manice LA, Colvin RA, Luster AD. Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4814-9. doi:
Intact TRL 9 and type I interferon signaling pathways are required to augment - Intact TRL 9 and type I interferon signaling pathways are required to augment
Wuest T, Austin BA, Uematsu S, Thapa M, Akira S, Carr DJ. J Neuroimmunol. 2006 Oct;179(1-2):46-52. Epub 2006 Aug 1.
Regulated expression of the interferon-beta gene in mice. - Regulated expression of the interferon-beta gene in mice.
Harkins RN, Szymanski P, Petry H, Brooks A, Qian HS, Schaefer C, Kretschmer PJ, Orme A, Wang P, Rubanyi GM, Hermiston TW. Gene Ther. 2008 Jan;15(1):1-11. Epub 2007 Jul 19.
Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates - Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates
Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ, Hogaboam CM. Am J Pathol. 2007 Apr;170(4):1152-64.
Cutting edge: Divergent cell-specific functions of MyD88 for inflammatory - Cutting edge: Divergent cell-specific functions of MyD88 for inflammatory
Gais P, Reim D, Jusek G, Rossmann-Bloeck T, Weighardt H, Pfeffer K, Altmayr F, Janssen KP, Holzmann B. J Immunol. 2012 Jun 15;188(12):5833-7.
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for - IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for
Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD, Weis EL, Passanese J, Wang WC, Gollnick SO, Dewhirst MW, Rose-John S, Repasky EA, Baumann H, Evans SS. J Clin Invest. 2011 Oct;121(10):3846-59.
A new murine model for bronchiolitis obliterans post-bone marrow transplant. - A new murine model for bronchiolitis obliterans post-bone marrow transplant.
Panoskaltsis-Mortari A, Tram KV, Price AP, Wendt CH, Blazar BR. Am J Respir Crit Care Med. 2007 Oct 1;176(7):713-23. Epub 2007 Jun 15.
A lymphotoxin-driven pathway to hepatocellular carcinoma. - A lymphotoxin-driven pathway to hepatocellular carcinoma.
Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M. Cancer Cell. 2009 Oct 6;16(4):295-308.